EDARAVONE IN ACUTE ISCHEMIC STROKE

A RANDOMIZED CONTROLLED CLINICAL TRIAL TO COMPARE THE SAFETY AND EFFICACY OF EDARAVONE IN ACUTE ISCHEMIC STROKE

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2009/091/000309

Enrollment

Registered

2010-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: EDARAVONE: 30 MG INFUSION BD FOR 2 WEEKS Control Intervention1: normal saline: 500 ml for 2 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Patients with acute ischemic stroke hospitalized between 6 and 72 hours of onset of stroke.

Exclusion criteria

Exclusion criteria: Patients with age less than 18 years, unclear time of onset, those who received any thrombolytic therapy, those with severe hepatic disease, renal dysfunction, pregnancy or lactating female.

Design outcomes

Primary

Measure	Time frame
Modified Rankin ScoreTimepoint: 90 days	—

Secondary

Measure	Time frame
All cause mortalityTimepoint: 90 days	—

Countries

India

Contacts

Public ContactPROF. RAKESH SHUKLA

rakeshshukla_rakesh@rediffmail.com05222257090

Outcome results